Where this chronic myeloid leukaemia information comes from | Cancer Research UK
Cancer Research UK on Google+ Cancer Research UK on Facebook Cancer Research UK on Twitter

Where this chronic myeloid leukaemia information comes from

Men and women discussing chronic myeloid leukaemia

On this page are the major sources of information that we use to put together this section about chronic myeloid leukaemia.

 

About our patient information

All our information is checked by cancer specialists and surgeons who specialise in treating cancer. The names of our specialist reviewers are at the end of this list. We also try to find patients to review all our sections. If you have had chronic myeloid leukaemia, live in the UK, and would like to become a patient reviewer, you can write to us by clicking on contact us.

 

Websites

Cancer Research UK
CancerStats Series

US National Cancer Institute
Information on the treatment of chronic myeloid leukaemia
www.cancer.gov/cancertopics/pdq/treatment/CML/Patient

Electronic Medicines Compendium
Information about cancer drugs
www.emc.medicines.org.uk

 

Books

Principles and practice of oncology (9th edition)
VT De Vita, S Hellman and SA Rosenberg
Lippincott, Williams and Wilkins, 2011

Essential haematology (6th edition)
V Hoffbrand and D Moss
Wiley-Blackwell 2011

Cancer and its management (6th edition)
J Tobias and D Hochhauser
Blackwell, 2010

 

UK and international guidelines

Dasatinib, nilotinib and standard-dose imatinib for the first line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70) (TA251)
National Institute for Health and Care Excellence (NICE), April 2012
Link to guidance on NICE website 

Dasatinib, high dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (TA241)
National Institute for Health and Care Excellence (NICE), August 2011
Link to NICE website

Guidance on use of nilotinib for newly diagnosed Philadelphia chromosome positive adult patients with CML in chronic phase
Scottish Medicines Consortium (SMC), August 2011
Link to guidance on SMC website

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatments and follow up. M Baccarani and M Dreyling. European Society of Medical Oncology working group. Annals of Oncology 21 (Supplement 5) v165–167, 2010

Recommendations for the management of BCR/ABL positive chronic myeloid leukaemia. 
J Goldman, British Committee for Standards in Haematology, July 2007

Referral for suspected cancer. A clinical practice guideline.
National Institute for Health and Care Excellence (NICE), June 2015
Link to the NICE Referral guidelines 

Imatinib for chronic myeloid leukaemia (TA70)
National Institute for Health and Care Excellence (NICE), October 2003
Link to imatinib guidance on NICE website

Improving outcomes in haematological cancers
National Institute for Health and Care Excellence (NICE), October 2003
Link to NICE haematological cancers manual

 

Articles and reviews

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. M Baccarani and others. Annals of Oncology, 2012, volume 23, supplement 7.

European LeukemiaNet recommendations for the management of chronic myeloid leukaemia: 2013. M Baccarani and others. Blood, 8 August 2013, volume 122, No 6, pp872-884.

Current role of stem cell transplantation in chronic myeloid leukaemia. A Gratwohl. Best Practice & Research Clinical Haematology, 2009, volume 22, pp431-443

Monitoring treatment of chronic myeloid leukaemia. M Baccarani and others. Haematologica, 2008, volume 93, issue 2, pp161-9

Imatinib treatment for chronic myeloid leukaemia: where do we go now? JE Cortes. Journal of Clinical Oncology, 2008, volume 26, issue 20, p3308. 

Favourable long term follow up results over 6 years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukaemia after failure of interferon alpha treatment.
A Hochhaus and others. Blood, 2008, volume 111, issue 3, p1039.

Updated estimate of survival and cost effectiveness for imatinib vs interferon alpha plus low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukaemia. SD Reed and others. Pharmacoeconomics, 2008, volume 26, issue 5, pp435-46.

 

Specialist reviewers

Dr Nilima Parry-Jones
Dr Prem Mahendra

 

Diagrams

Dee McLean – MeDee Art, Medical Illustration

Rate this page:
Submit rating
Rate this page
Rate this page for no comments box
Please enter feedback to continue submitting
Send feedback
Question about cancer? Contact our information nurse team

No Error

Updated: 7 July 2015